Transcatheter mitral valve repair (TMVR) is among a rising class of catheter-based therapies for heart defects and valve disorders, providing a critical treatment option for patients with severe mitral regurgitation associated with obesity, hypertension, and type 2 diabetes who are not suitable candidates for surgery. The TMVR market in India is projected to grow at a compound annual growth rate (CAGR) of 17% through 2036, forecasts GlobalData, a leading data and analytics company.

GlobalData report, “Transcatheter Mitral Valve Repair (TMVR) Market Size by Segments, Share, Regulatory, Reimbursement, Interventions and Forecast to 2036,” reveals that India accounted for 10% of the Asia-Pacific (APAC) TMVR market in 2024. The growth highlights the combination of rising disease prevalence, technological advancements, the appeal of less disruptive procedures and improving healthcare infrastructure.

Meril Life Sciences, an India-based multinational medical device company, has recently launched India’s first transcatheter edge-to-edge repair (TEER) system “MyClip.” This marks a significant step forward in the country’s growing proficiency in structural heart conditions. It also represents a major advancement in the management of severe mitral regurgitation, providing enhanced patient outcomes.

Shamreen Parween, Medical Devices Analyst at GlobalData, comments, “Advanced treatments for heart disease are broadening the scope of care by providing safe and effective solutions to a wider and more diverse patient population. The shift from traditional open-heart surgery to minimally invasive treatments is revolutionizing patient care, offering shorter recovery times and expanding access to individuals who may not be suitable candidates for conventional surgical procedures. These innovative approaches are reshaping the management of structural heart disease and fueling substantial market growth through increased demand.”

The MyClip device facilitates precise closure of the mitral valve flaps, which helps prevent the backflow of oxygenated blood into the lungs. Although the device has seen early adoption, it is imperative to train cardiologists and enhance TEE-based imaging expertise to broaden the application of this life-saving therapy across the country.

Parween concludes: “As more hospitals and doctors across India adopt these advanced heart treatments, patients gain better access to life saving care. This growing acceptance is driving steady progress in the healthcare system, making heart condition management more efficient, innovative and available to more people than ever before.”